VRAX — Virax Biolabs Group Limited
$0.61
$-0.06 (-8.25%)
Virax Biolabs Group Limited, a biotechnology company, focuses on immune response detection, T cell immune profiling, and the development of in vitro diagnostic technologies for viral and immune-mediated diseases in the United Kingdom, the United States, and China. The company offers ViraxImmune, a T cell-based immune profiling and diagnostic platform for post-acute infection syndromes, including long COVID, myalgic encephalomyelitis / chronic fatigue syndrome, and post-treatment Lyme disease.
Market Cap
$823939.00
Forward P/E
-0.1x
52-Week Range
N/A
VRAX Price History
Revenue vs. Net Income
$12.4K
Revenue · FY2026
Annual. Net margin is shown under each year.
Free Cash Flow
-$4.9M
FCF · FY2026
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
-76.8%
ROCE · FY2026
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
11.1x
Assets ÷ liabilities · FY2026
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
2059.8%
CapEx · FY2026
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+166.5%
Dilution · FY2026
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
